I'd say the most disappointing part of this result was not the result itself but the confirmation that the significant growth many of us here were banking on 12 months ago has not come to fruition. In May 2019 investors here were focused on and regularly discussing break even in the near term. Three back-to-back landmark deals and a roadmap thrown in to boot. But here we are 12 months later, with a more diluted MC and lower share price. Investors need to see sustained returns on their investment or they move elsewhere. That's the bottom line.
I'm still comfortable as a holder since mid 2018 as I like the sector and verticals 1ST operate in. I do also understand that what 1ST is building takes time. But there's still a tolerance limit to this when site growth doesn't translate to revenue and cash receipts. It's the opportunity cost that @T.E.P. mentions above. Heading into FY21 I'd like to see more regular sale updates and crystal clear reports. The spending we've just seen in Q3 could have been much better explained for a start.
Telehealth has presented a timely opportunity for Q4 numbers so I hope Klaus and the team are all guns blazing to capitalise. We also need to see those landmark deals (now all more than 12 months underway) coming through as payments.
1ST Price at posting:
2.7¢ Sentiment: Hold Disclosure: Held
